Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 352 articles:
HTML format



Single Articles


    December 2026
  1. DI FILIPPO M, Masillo V, Di Sabatino E, Cordioli C, et al
    Impact of 2024 Revisions of Multiple Sclerosis Diagnostic Criteria in People With Radiologically Isolated Syndrome.
    Neurology. 2026;107:e218691.
    PubMed     Abstract available


  2. HEDSTROM AK, Olsson T, Alfredsson L
    Occupational Exposure to Petroleum-Derived Lubricants and Risk of Multiple Sclerosis.
    Neurology. 2026;107:e218718.
    PubMed     Abstract available


  3. FRASE S, Wiendl H
    Toward a Biology-Driven Diagnosis of Multiple Sclerosis: What the 2024 McDonald Criteria Mean for Radiologically Isolated Syndrome.
    Neurology. 2026;107:e218758.
    PubMed    


  4. MARRIE RA
    Timing Is Everything: Occupational Petrolatum-Based Lubricant Exposure and Multiple Sclerosis.
    Neurology. 2026;107:e218747.
    PubMed    


  5. ROTSTEIN DL, Marrie RA, Tremlett H, Vyas MV, et al
    Factors Associated With Rate of Multiple Sclerosis Onset in a Cohort With Prior Infectious Mononucleosis Identified in Administrative Data.
    Neurology. 2026;107:e218756.
    PubMed     Abstract available


  6. PIURA YD, Elgenidi A, Tipton PW, Satyadev N, et al
    Performance of Diagnostic Criteria for Autoimmune Encephalitis in Patients With Suspected Rapidly Progressive Dementia.
    Neurology. 2026;107:e218783.
    PubMed     Abstract available


  7. JOKUBAITIS VG, Palladino R
    From Exposure to Disease: Prevalence of Post-Mononucleosis Multiple Sclerosis.
    Neurology. 2026;107:e218853.
    PubMed    


  8. TANIGUCHI Y, Inoue H, Takemoto N, Madokoro Y, et al
    Teaching Video NeuroImage: Posture-Dependent Hypernasal Dysarthria With Velopharyngeal Insufficiency in Myasthenia Gravis.
    Neurology. 2026;107:e218744.
    PubMed    


    November 2026
  9. CORTESE R, Bianchi A, de Mauro A, Luchetti L, et al
    Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
    Neurology. 2026;107:e218673.
    PubMed     Abstract available


  10. SHI JQ, Hong Y, Zhao HD, Jiang T, et al
    Reader Response: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2026;107:e214850.
    PubMed    


  11. SIEGLER JE, Galetta SL
    Editors' Note: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2026;107:e218759.
    PubMed    


  12. KRENN M, Wagner M, Cetin H
    Author Response: Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2026;107:e214896.
    PubMed    


  13. ABBATEMARCO JR, Begum F, Villalba JA, Davis E, et al
    Establishing Potosi Virus as a Human Pathogen: Fatal Neuroinvasive Disease in a B-Cell-Depleted Patient.
    Neurology. 2026;107:e218683.
    PubMed     Abstract available


  14. SEGAL Y, Aksamit AJ, McCarter SJ, Syc-Mazurek SB, et al
    "Railroad Track" Brain Fluorodeoxyglucose-PET Sign in Antiphospholipid Syndrome-Related Posterior Cortical Atrophy.
    Neurology. 2026;107:e218621.
    PubMed    


  15. REYES-LEIVA D, Carbayo A, Vesperinas A, Caballero-Martinez F, et al
    Disease Control in Generalized Myasthenia Gravis: Consensus Definition, Evolution, and Patient Characterization.
    Neurology. 2026;107:e218557.
    PubMed     Abstract available


  16. PREZIOSA P, Meani A, Tedone N, Gattuso I, et al
    Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218641.
    PubMed    


    October 2026
  17. APAP MANGION S, Wade C, Coles D, Burton R, et al
    Developing Interim Outcome Measures for Multi-Arm Multistage Clinical Trials in Multiple Sclerosis.
    Neurology. 2026;107:e218426.
    PubMed     Abstract available


  18. GRAVESTEIJN AS, Nauta IM, Stob M, Wilmsen N, et al
    Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis in the LIMS Study: A 24-Month Follow-Up.
    Neurology. 2026;107:e218542.
    PubMed     Abstract available


  19. OOI JCE, Leong SY, Pairan MS, Tan KY, et al
    Anti-Contactin-Associated Protein-Like-2 Antibody-Positive Morvan Syndrome With Myokymia in Thymoma-Associated Myasthenia Gravis.
    Neurology. 2026;107:e218562.
    PubMed    


  20. BARTER KM, Thant A, Pitt M, Thotakura V, et al
    Pearls & Oy-sters: Diagnosis of Pediatric Tumefactive Multiple Sclerosis With MRI Biomarkers.
    Neurology. 2026;107:e218575.
    PubMed     Abstract available


  21. JAIN K, Storelli L, Valsasina P, Preziosa P, et al
    Disentangling Age-Related and Disease-Specific Effects on Upper Cervical Cord Area in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218517.
    PubMed     Abstract available


  22. VRENKEN H
    Separating Disease Effects From Aging in Spinal Cord Atrophy in Multiple Sclerosis.
    Neurology. 2026;107:e218605.
    PubMed    


  23. EL MAHDAOUI S, Pontieri L, Romme Christensen J, Alabdalridha H, et al
    Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study.
    Neurology. 2026;107:e218545.
    PubMed     Abstract available


  24. LIAMPAS A, Artemiadis A, Tseriotis VS, Prados F, et al
    Prevalence of Slowly Expanding Lesions in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Neurology. 2026;107:e218474.
    PubMed     Abstract available


  25. SUKHONPANICH N, Ngamsombat C, Buathong S, Thaneerat N, et al
    Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.
    Neurology. 2026;107:e218507.
    PubMed     Abstract available


    September 2026
  26. FERNANDEZ V, Pappolla A, Carbonell-Mirabent P, Castillo M, et al
    Refining Treatment Monitoring in Patients With Relapsing Multiple Sclerosis Based on Changes on Neurofilament Light Chain Z-Scores.
    Neurology. 2026;107:e218451.
    PubMed     Abstract available


  27. LAUERER M, Voon CC, McGinnis J, Sepp D, et al
    The Prognostic Value of Paramagnetic Rim Lesions in People With Multiple Sclerosis.
    Neurology. 2026;107:e218428.
    PubMed     Abstract available


  28. SOLOMON AJ, Brownlee WJ, Viswanathan S, Fadda G, et al
    Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting.
    Neurology. 2026;107:e218425.
    PubMed     Abstract available


  29. GRANBERG T
    Paramagnetic Rim Lesions and Their Predictive Value of Future Progression in People With Multiple Sclerosis.
    Neurology. 2026;107:e218582.
    PubMed    


  30. FURLAN R, Rossi E
    Longitudinal Neurofilament Light Chain Z-Score Dynamics: Bridging the Gap Between Research and Routine Monitoring in Multiple Sclerosis.
    Neurology. 2026;107:e218505.
    PubMed    


  31. HACOHEN Y, Androdias G, Arrambide G, Bruijstens AL, et al
    De-Escalating and Discontinuing Immunotherapies in Patients With NMOSD and MOGAD.
    Neurology. 2026;107:e218482.
    PubMed     Abstract available


  32. MOHAMED MI, Sameh R, Farghaly D, Ashraf B, et al
    Autoimmune Neurologic Disorders and the Risk of Alzheimer, Vascular, and Other Dementias: A Comprehensive Systematic Review and Meta-Analysis (P2-13.006).
    Neurology. 2026;107:e218536.
    PubMed    


  33. KWON S, Kim BS, Han K, Heo NJ, et al
    Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis: A Nationwide Cohort Study in South Korea.
    Neurology. 2026;107:e218377.
    PubMed     Abstract available


  34. GIANNOCCARO MP, Serra L, Grondona AG, Ballestracci C, et al
    Accuracy of Antibody Testing in Myasthenia Gravis: The ADAM Study.
    Neurology. 2026;107:e218301.
    PubMed     Abstract available


  35. VINCENT A
    Cell-Based Assays: The New Gold Standard for Diagnosing Myasthenia Gravis?
    Neurology. 2026;107:e218495.
    PubMed    


    August 2026
  36. BALSHI A, Alves C, Ullrich NJ, Benson LA, et al
    Child Neurology: A Case of Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis by 2024 Criteria.
    Neurology. 2026;107:e218240.
    PubMed     Abstract available


  37. SCHOOF L, Heijnen R, Hogenboom L, Van Kempen ZLE, et al
    Value of Annual MRI Monitoring in Patients With Multiple Sclerosis Treated With Ocrelizumab: A Number Needed to Scan Analysis.
    Neurology. 2026;107:e218379.
    PubMed     Abstract available


  38. PRESSLER H, Stascheit F, Aigner A, Doksani P, et al
    Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.
    Neurology. 2026;107:e218308.
    PubMed     Abstract available


  39. MCLAREN NP, Rosati M, Zhong W, Hussain S, et al
    Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis.
    Neurology. 2026;107:e218351.
    PubMed     Abstract available


  40. KIMURA A, Takekoshi A, Maekawa Y, Tanaka K, et al
    Involvement of TNFRSF9 in the Pathogenesis of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2026;107:e218306.
    PubMed     Abstract available


  41. PREZIOSA P, Meani A, Tedone N, Gattuso I, et al
    Gray Matter Damage and Long-Term Disability, Cognitive Outcome, and Survival in Patients With Multiple Sclerosis.
    Neurology. 2026;107:e218310.
    PubMed     Abstract available


    July 2026
  42. ENGELS D, Schindler P, Havla J, Fischer K, et al
    Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.
    Neurology. 2026;107:e218199.
    PubMed     Abstract available


  43. GUINEBRETIERE O, Yang F, Wei D, Calonge Q, et al
    Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003-2022).
    Neurology. 2026;107:e218072.
    PubMed     Abstract available


  44. BOS L, Wink AM, Cole JH, Pontillo G, et al
    Mediation Analysis Between Brain Age, Disease-Modifying Factors, and Disability and Cognitive Performance in Multiple Sclerosis.
    Neurology. 2026;107:e218161.
    PubMed     Abstract available


  45. ALLEN JA, Eftimov F, Querol L, Sommer C, et al
    Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
    Neurology. 2026;107:e218159.
    PubMed     Abstract available


  46. SCHARF A, Cohen JA, Marrie RA, Miller AE, et al
    Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.
    Neurology. 2026;107:e218183.
    PubMed     Abstract available


  47. TINTORE M, Rovira A
    Redefining Multiple Sclerosis: Toward a Biologically Driven Diagnosis.
    Neurology. 2026;107:e218210.
    PubMed    


  48. MIRCHI A, Vossough A, Liu GT, Narula S, et al
    Pearls & Oy-sters: Radiologic Lag in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2026;107:e218254.
    PubMed     Abstract available


    June 2026
  49. O'CONNOR L, Gabrysch K, Wikstrom AK, Rostedt Punga A, et al
    Risk of Myasthenia Gravis Exacerbation During Pregnancy and Postpartum: A Nationwide Cohort Study.
    Neurology. 2026;106:e218082.
    PubMed     Abstract available


  50. SHARMIN S, Roos I, Labauge PM, Filippi M, et al
    Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.
    Neurology. 2026;106:e218056.
    PubMed     Abstract available


  51. LAULETTA A, Rossini E, Beretta F, Damato V, et al
    Comparative Study of Sporadic and Immune Checkpoint Inhibitor-Related Forms of Myasthenia Gravis-Myositis Overlap Syndrome.
    Neurology. 2026;106:e218081.
    PubMed     Abstract available


  52. ROUX T, Lejeune FX, Casey R, Audoin B, et al
    French NOMADMUS Cohort Overview: Landscape Evolution of AQP4+NMOSD and MOGAD From 2010 to 2024.
    Neurology. 2026;106:e218073.
    PubMed     Abstract available


  53. GOMBOLAY GY, Rubin JP
    Sometimes Kids Really Are Just Little Adults: Early Access to High-Efficacy Therapy Decreases Disability in Pediatric Multiple Sclerosis.
    Neurology. 2026;106:e218168.
    PubMed    


  54. YAO Y, Li Y, Liu J, Ji Z, et al
    Longitudinal Spinal Cord Atrophy in Patients With Neuromyelitis Optica Spectrum Disorder and Its Association With Rituximab Treatment.
    Neurology. 2026;106:e218120.
    PubMed     Abstract available


  55. KIM W, Watt CL, Fung SG, Yoo S, et al
    Multiple Sclerosis and Outpatient Physician Care in the Last Years of Life: A Population-Based Study.
    Neurology. 2026;106:e218067.
    PubMed     Abstract available


  56. LANZANTE M, Cerase A, de Mauro A, Forti A, et al
    Bridging the Gap: Balo Concentric Sclerosis-Like Leukoencephalopathy in Chronic Cocaine Use: A 1-Year Clinical and Imaging Follow-Up of 2 Cases.
    Neurology. 2026;106:e218068.
    PubMed     Abstract available


  57. VAN STEENHOVEN RW, Bastiaansen AEM, Kerstens J, Crijnen YS, et al
    Autoimmune Encephalitis as Treatment-Responsive Cause of Rapidly Progressive Dementia: A Multicenter Prospective Cohort Study.
    Neurology. 2026;106:e214933.
    PubMed     Abstract available


    May 2026
  58. GAVOILLE A, Kerbrat A, Edan G, Le Page E, et al
    Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2026;106:e214943.
    PubMed     Abstract available


  59. KVISTAD CE, Krakenes T, Holmoy T, Eidem LE, et al
    Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS).
    Neurology. 2026;106:e214915.
    PubMed     Abstract available


  60. PLUCHINO S, Mozafari S
    Early Human Intrathecal Mesenchymal Stem Cell Study in Progressive Multiple Sclerosis Faces Delivery Challenges.
    Neurology. 2026;106:e214955.
    PubMed    


  61. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214917.
    PubMed    


    April 2026
  62. TOURNIER A, Gavoille A, Pique J, Levraut M, et al
    Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD, and MS.
    Neurology. 2026;106:e214806.
    PubMed     Abstract available


  63. REMIJN-NELISSEN L, Bakker WR, van den Hout WB, van Gelder T, et al
    Efficacy of Pyridostigmine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
    Neurology. 2026;106:e214865.
    PubMed     Abstract available


  64. REMIJN-NELISSEN L, Bakker WR, van Gelder T, Moes DJAR, et al
    Efficacy and Safety of Amifampridine in Myasthenia Gravis: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial.
    Neurology. 2026;106:e214715.
    PubMed     Abstract available


  65. PATEL AN, Kesselheim AS, Rome BN
    Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in Medicare.
    Neurology. 2026;106:e214834.
    PubMed     Abstract available


  66. BOURDETTE D, Hartung DM
    Industry Payments to Physicians Alter the Care of Patients With Multiple Sclerosis: It's Time to Cut Financial Ties.
    Neurology. 2026;106:e214920.
    PubMed    


  67. DE JONG DJ, Schoonheim MM
    The Role of Wearable Devices to Identify Patients at High Risk of Disease Progression in Multiple Sclerosis.
    Neurology. 2026;106:e214742.
    PubMed    


  68. FITZGERALD KC, Sanjayan M, Dewey BE, Guha Niyogi P, et al
    Association of Changes in Activity Patterns With Brain Atrophy and Disability Progression in People With Multiple Sclerosis.
    Neurology. 2026;106:e214678.
    PubMed     Abstract available


  69. KIM SH, Lee EJ, Lim YM, Kim H, et al
    Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.
    Neurology. 2026;106:e214792.
    PubMed     Abstract available


  70. JACOBS BM, Schalk L, Tregaskis-Daniels E, Scalfari A, et al
    Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.
    Neurology. 2026;106:e214708.
    PubMed     Abstract available


  71. SIRIRATNAM P, Jokubaitis VG, Van Der Walt A, Sanfilippo PG, et al
    Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2026;106:e214707.
    PubMed     Abstract available


  72. MARTINEZ SOSA S, Tisavipat N, Betting T, Guo Y, et al
    Pearls & Oy-sters: Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis.
    Neurology. 2026;106:e214794.
    PubMed     Abstract available


  73. LEODORI G, Maccarrone D, Mancuso M, De Bartolo MI, et al
    Resting-State EEG Microstates as Dynamic Biomarkers of Network Dysfunction and Cognitive Impairment in Patients With Multiple Sclerosis.
    Neurology. 2026;106:e214778.
    PubMed     Abstract available


  74. PEDERSON AM, Buto P, Zimmerman SC, Velez M, et al
    Type 1 Diabetes and Incident Dementia: An Analysis in the All of Us Cohort.
    Neurology. 2026;106:e214805.
    PubMed     Abstract available


  75. DESCHAMPS R, Papeix C, Demortiere S, Lardeux P, et al
    Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria.
    Neurology. 2026;106:e214753.
    PubMed     Abstract available


  76. ALFREDSSON L, Johansson E, Olsson T, Stridh P, et al
    Occupational Exposure to Industrial Dust and Rates of Multiple Sclerosis.
    Neurology. 2026;106:e214762.
    PubMed     Abstract available


    March 2026
  77. BROWNLEE WJ, Maccarrone D, Nistri R, Yam C, et al
    Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.
    Neurology. 2026;106:e214688.
    PubMed     Abstract available


  78. ZHANG H, Janszky I, Arkema EV, Wang H, et al
    Autoimmune Diseases and Incident Spontaneous Subarachnoid Hemorrhage: A Swedish Population-Based Cohort Study.
    Neurology. 2026;106:e214679.
    PubMed     Abstract available


  79. MILLER AE
    The 2024 McDonald Criteria for Diagnosis of Multiple Sclerosis: The Rubber Meets the Road.
    Neurology. 2026;106:e214688.
    PubMed    


  80. CHANDRA A, Acharya S, Chandra A
    Global & Community Health: Diagnosis and Management of Multiple Sclerosis in Nepal: Overcoming Barriers Through Local Adaptations.
    Neurology. 2026;106:e214743.
    PubMed     Abstract available


  81. PARAMASIVAN NK, Basal E, LaFrance-Corey RG, Arlt FA, et al
    Clinical Insights Into CASPR1 and CASPR1/Contactin-1 Complex Autoimmune Nodopathies.
    Neurology. 2026;106:e214403.
    PubMed     Abstract available


  82. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2026;106:e214694.
    PubMed    


    February 2026
  83. TEO KSH, Kwan MYK, Qu D, Lim LHP, et al
    Patient Perspective: Words That Matter: Reflections on a Patient's Experiences With Guillain-Barre Syndrome.
    Neurology. 2026;106:e214685.
    PubMed     Abstract available


  84. LOCKHART A, Pisa M, Drakesmith H, DeLuca GC, et al
    Iron-Rim Lesions in the Optic Chiasm in Multiple Sclerosis: A Neuropathologic Case Series.
    Neurology. 2026;106:e214515.
    PubMed     Abstract available


  85. CAGOL A, Granziera C
    Turning Our Gaze to the Anterior Visual Pathway: Iron Rim Lesions Come Into View in Multiple Sclerosis.
    Neurology. 2026;106:e214590.
    PubMed    


  86. NISTRI R, Cacciaguerra L, Sacco S, Virupakshaiah A, et al
    Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD.
    Neurology. 2026;106:e214410.
    PubMed     Abstract available


    January 2026
  87. BOS L, Wink AM, Cole JH, Strijbis EMM, et al
    Association of Brain Age With Physical Disability and Cognitive Impairment in People With Multiple Sclerosis of the Same Age.
    Neurology. 2026;106:e214527.
    PubMed     Abstract available


  88. LANGER-GOULD A, Li BH, Smith JB, Nielsen AS, et al
    Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis.
    Neurology. 2026;106:e214473.
    PubMed     Abstract available


  89. BARTELS F, Tapuc A, Rentzsch K, Duong SL, et al
    Memory Deficits in Cancer Patients With Serum NMDA Receptor Autoantibodies.
    Neurology. 2026;106:e214490.
    PubMed     Abstract available


  90. MOCCIA M, Silbermann E
    Can Once-Yearly Rituximab Dosing Be "Enough" for Most People With Relapsing Multiple Sclerosis?
    Neurology. 2026;106:e214586.
    PubMed    


  91. SPAIN RI, Paz Soldan MM, Freedman MS, Repovic P, et al
    Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.
    Neurology. 2026;106:e214454.
    PubMed     Abstract available


  92. BRIGGS FBS, Amezcua L
    Alpha Lipoic Acid in Multiple Sclerosis: It's All in the Details.
    Neurology. 2026;106:e214578.
    PubMed    


    December 2025
  93. HUANG X, Yu ZH, Cui Y, Zhang H, et al
    Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis.
    Neurology. 2025;105:e214428.
    PubMed     Abstract available


  94. DAMULINA A, Opriessnig P, Pirpamer L, Demjaha R, et al
    Association of CSF Kappa-Free Light Chains With Cortical and Periventricular Brain Damage in Multiple Sclerosis.
    Neurology. 2025;105:e214433.
    PubMed     Abstract available


  95. TRENTADUE T, Martinez Sosa S, Itoh CY, Modi T, et al
    Clinical Reasoning: A 30-Year-Old Female Patient With Multiple Sclerosis Presenting With Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia.
    Neurology. 2025;105:e214429.
    PubMed     Abstract available


  96. DE MEO E, Addazio I, Portaccio E, Bonacchi R, et al
    Disability Worsening Phenotypes in Multiple Sclerosis and Impact of Disease-Modifying Treatments.
    Neurology. 2025;105:e214408.
    PubMed     Abstract available


    November 2025
  97. DIMAURO KA, Manohar N, Aboseif A, Shah C, et al
    Leucine Zipper 4 Autoantibody-Associated Myeloneuropathy With Multiple Cranial Neuropathies and Longitudinally Extensive Tractopathy.
    Neurology. 2025;105:e214384.
    PubMed    


  98. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;105:e214158.
    PubMed    


  99. VILASECA A, Dalmau JO, Benarroch E
    What Are the Proposed Mechanisms Contributing to the Manifestations of Anti-NMDAR Encephalitis?
    Neurology. 2025;105:e214232.
    PubMed     Abstract available


  100. TASHIRO T, Ogata H, Fukami Y, Maimaitijiang G, et al
    Clinical, Electrophysiologic, and Pathologic Features of Anti-Contactin-Associated Protein 1 Autoimmune Nodopathy.
    Neurology. 2025;105:e214143.
    PubMed     Abstract available


  101. KOZIK V, Dreiling M, Muller D, Tiedge O, et al
    Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment: A Cross-Sectional Study.
    Neurology. 2025;105:e214217.
    PubMed     Abstract available


  102. HOGUE O, Zelinsky M, Sonneborn C, Anantasagar T, et al
    Association of Statistical Methodology and Design in Preclinical Animal Studies With Successful Translation Into Clinical Phase 2 Trials.
    Neurology. 2025;105:e214250.
    PubMed     Abstract available


  103. VOROBYEV A, Buciuc M, Perez Giraldo GS, Grewal P, et al
    Clinical Reasoning: A 56-Year-Old Woman With Right-Sided Weakness and Recurrent MRI Lesions.
    Neurology. 2025;105:e214293.
    PubMed     Abstract available


  104. PIERRET C, Leray E
    Author Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210260.
    PubMed    


  105. GANESH A, Galetta SL
    Editors' Note: Understanding Cancer Risk Among Patients With Multiple Sclerosis.
    Neurology. 2025;105:e214342.
    PubMed    


  106. SEJVAR JJ
    Guillain-Barre Syndrome: Grasping the "Rarity" of Outbreaks.
    Neurology. 2025;105:e214268.
    PubMed    


  107. SONG Y, Wang L, Xuan Z
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210222.
    PubMed    


  108. FENG Q
    Reader Response: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e210223.
    PubMed    


    October 2025
  109. PORTACCIO E, Betti M, De Meo E, Pasto L, et al
    Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2025;105:e213977.
    PubMed     Abstract available


  110. O'NEILL KA, Charvet L, Waltz M, George A, et al
    Cognitive Function in People With Pediatric Multiple Sclerosis Over 2 Years.
    Neurology. 2025;105:e214142.
    PubMed     Abstract available


  111. OLIVIERI E, Muller J, Toosy AT
    Predicting Disability Using PIRA in Multiple Sclerosis: Is It as Straightforward as It Appears?
    Neurology. 2025;105:e214206.
    PubMed    


  112. PORTACCIO E, Amato MP
    Moving Closer to the Prevention of Cognitive Disability in People With Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;105:e214244.
    PubMed    


  113. LINDROOS JLV, Bjork MH, Cohen JM, Danielsson KC, et al
    Obstetric and Neonatal Outcomes in Patients With Maternal Myasthenia Gravis: A Nationwide Cohort Study.
    Neurology. 2025;105:e214139.
    PubMed     Abstract available


  114. SAHI N, Ciccarelli O, Houlden H, Chard DT, et al
    Unlocking Multiple Sclerosis Genetics: From Susceptibility to Severity.
    Neurology. 2025;105:e214141.
    PubMed     Abstract available


  115. KRENN M, Wagner M, Schuller H, Pugna I, et al
    Screening for Congenital Myasthenic Syndromes in Adults With Seronegative Myasthenia Gravis Using Next-Generation Sequencing.
    Neurology. 2025;105:e214177.
    PubMed     Abstract available


  116. SERRAO C, Rodrigues R, Guerreiro CL, Oliveira J, et al
    Pearls & Oy-sters: Adult-Onset Coats Plus: A Case of Leukoencephalopathy With Calcifications, a Tumefactive Brain Lesion, and a Presumed Autoimmune Disease.
    Neurology. 2025;105:e214124.
    PubMed     Abstract available


  117. NAUTIYAL K, Roy Chowdhury S, Meena R, Reddy N, et al
    Child Neurology: Parainfectious Anti-NMDAR Encephalitis With Anti-MOG and Anti-AQP4 Seropositivity in an Infant.
    Neurology. 2025;105:e214125.
    PubMed     Abstract available


  118. BSTEH G, Hegen H, Krajnc N, Fottinger F, et al
    Association Between Retinal Layer Atrophy With Clinical and Radiologic Progression in People With Relapsing Multiple Sclerosis.
    Neurology. 2025;105:e214069.
    PubMed     Abstract available


  119. OVED K, Denkberg G, Pinzur L, Chroni E, et al
    Subunit-Specific Immunodominance in Clinically Distinct Populations With AChR+ Myasthenia Gravis: A Multiparametric Cross-Sectional Analysis.
    Neurology. 2025;105:e214150.
    PubMed     Abstract available


    September 2025
  120. THAKOLWIBOON S, Redenbaugh V, Chen B, Hewitt S, et al
    Outcomes After Acute Plasma Exchange for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Neurology. 2025;105:e213903.
    PubMed     Abstract available


  121. CORTESE R, Sforazzini F, Gentile G, de Mauro A, et al
    Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated Disease.
    Neurology. 2025;105:e214075.
    PubMed     Abstract available


  122. RENNER B, Verter ED, Absinta M, Daboul L, et al
    Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.
    Neurology. 2025;105:e213912.
    PubMed     Abstract available


  123. CHARD DT
    Diagnosing Multiple Sclerosis: An Imperfect but Evolving Process.
    Neurology. 2025;105:e214057.
    PubMed    


  124. MAREFI A, Grasso EA, Canna SW, Behrens EM, et al
    Clinical Reasoning: A 9-Year-Old Girl With CNS Immune Dysregulation.
    Neurology. 2025;105:e213999.
    PubMed     Abstract available


    August 2025
  125. HACOHEN Y, Ciccarelli O, Kunchok AC
    Diagnostic Criteria for Autoimmune Encephalitis in Children: Challenges and Need for Clinical Expertise.
    Neurology. 2025;105:e213946.
    PubMed    


  126. SIEGLER JE, Galetta SL
    Editors' Note: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e213926.
    PubMed    


  127. MENON D, Bril V, Barnett-Tapia C
    Author Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e210073.
    PubMed    


  128. XU L, Zhou B, Xu Y
    Reader Response: Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2025;105:e210041.
    PubMed    


  129. GAVOILLE A, Leray E, Marignier R, Rollot F, et al
    Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.
    Neurology. 2025;105:e213907.
    PubMed     Abstract available


  130. BSTEH G, Hegen H
    Bridging the Sex Gap: Confronting Therapeutic Inertia in Women With Multiple Sclerosis.
    Neurology. 2025;105:e214073.
    PubMed    


  131. AL-ARAJI S, Moccia M, Jha A, Zhang L, et al
    Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;105:e213967.
    PubMed     Abstract available


  132. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;105:e213909.
    PubMed    


  133. CORTESE M, Peng X, Edan G, Freedman MS, et al
    Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression.
    Neurology. 2025;105:e213905.
    PubMed     Abstract available


  134. ROBIN C, Rollot F, Lefort M, Casey R, et al
    Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis.
    Neurology. 2025;105:e213744.
    PubMed     Abstract available


  135. BOURDETTE D, Wooliscroft L
    Late-Onset Multiple Sclerosis: Is Disease-Modifying Therapy Indicated?
    Neurology. 2025;105:e213971.
    PubMed    


  136. CABRAL A, Lopes da Mota C, Rodrigues Casanova S, Martins de Campos A, et al
    Pearls & Oy-Sters: Pan-Neurofascin Nodo-Paranodopathy Presenting as Fulminant Guillain-Barre Syndrome.
    Neurology. 2025;105:e213848.
    PubMed     Abstract available


    July 2025
  137. WU L, Jiang W, Du R, Liu Y, et al
    Clinical Reasoning: Acute and Progressive Cognitive Decline in a 38-Year-Old Man.
    Neurology. 2025;105:e213871.
    PubMed     Abstract available


  138. PETERSSON M, Jons D, Feresiadou A, Ilinca A, et al
    Nicotine, Alcohol Consumption, and Risk of Myasthenia Gravis: Results From the Swedish Nationwide GEMG Study.
    Neurology. 2025;105:e213771.
    PubMed     Abstract available


  139. ZHOU J, Nilius S, Pilipczuk O, Scowcroft A, et al
    Treatment Patterns and Disease Burden of Juvenile Myasthenia Gravis in the United States: A Cohort Study Using Health Care Claims Databases.
    Neurology. 2025;105:e213736.
    PubMed     Abstract available


  140. JIA A, Price TR, Rosner J, Broderick C, et al
    Journal Club: Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2025;105:e213663.
    PubMed     Abstract available


    June 2025
  141. GOYNE C, Fair AE, Yilmaz D, Race J, et al
    Epigenetic Aging in Pediatric-Onset Multiple Sclerosis.
    Neurology. 2025;104:e213673.
    PubMed     Abstract available


  142. JUL JARBAEK NIELSEN J, Levison L, Andersen H
    Mortality in Myasthenia Gravis in Denmark From 1985 to 2020: A Population-Based Cohort Study.
    Neurology. 2025;104:e213745.
    PubMed     Abstract available


  143. YEH EA
    Accelerated Aging in Children With Multiple Sclerosis: Can We Stop the Clock?
    Neurology. 2025;104:e213840.
    PubMed    


  144. KRIJNEN EA, Jelgerhuis J, Van Dam M, Bouman PM, et al
    Evolution of Cortical Lesions and Function-Specific Cognitive Decline in People With Multiple Sclerosis.
    Neurology. 2025;104:e213650.
    PubMed     Abstract available


    May 2025
  145. VAN NEDERPELT DR, Bos L, Mattiesing RM, Strijbis EMM, et al
    Multiple Sclerosis-Specific Reference Curves for Brain Volumes to Explain Disease Severity.
    Neurology. 2025;104:e213618.
    PubMed     Abstract available


  146. LANGER-GOULD A, Li BH, Smith JB, Kanter MH, et al
    Racial Inequities, Multiple Sclerosis, and Implementation of a Novel Treatment Algorithm at the Health System Level.
    Neurology. 2025;104:e213607.
    PubMed     Abstract available


  147. KAPPOS L, Yiu S, Dahlke F, Coetzee T, et al
    Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.
    Neurology. 2025;104:e213558.
    PubMed     Abstract available


  148. FOX RJ, Rudick RA
    A Newly Validated Gold Standard for Measuring Multiple Sclerosis Disability Worsening.
    Neurology. 2025;104:e213672.
    PubMed    


  149. DINOTO A, Cacciaguerra L, Vorasoot N, Redenbaugh V, et al
    Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
    Neurology. 2025;104:e213557.
    PubMed     Abstract available


  150. VU AP, Kapadia RK, Roberts JI
    Pearls & Oy-sters: Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Presenting as Encephalomyelitis With Leptomeningeal Enhancement.
    Neurology. 2025;104:e213662.
    PubMed     Abstract available


  151. MARRIE RA, Sharma M, Cutter GR, Fox RJ, et al
    Perspectives of People With Multiple Sclerosis Regarding Data Linkage and Sharing.
    Neurology. 2025;104:e213587.
    PubMed     Abstract available


  152. CHAGGAR G, Waldner D, Scozzafava J, Harrison R, et al
    Teaching NeuroImage: Severe Enterovirus Encephalitis as a Complication of Ocrelizumab Treatment for Multiple Sclerosis.
    Neurology. 2025;104:e213585.
    PubMed    


  153. NEWSOME SD, Krzystanek E, Selmaj KW, Dufek M, et al
    Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
    Neurology. 2025;104:e213574.
    PubMed     Abstract available


  154. ZARA P, Chessa P, Deiana GA, Morette AM, et al
    Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice.
    Neurology. 2025;104:e213498.
    PubMed     Abstract available


  155. GUINEBRETIERE O, Pierret C, Calonge Q, Januel E, et al
    Updated Multiple Sclerosis Incidence in France, 2011-2021.
    Neurology. 2025;104:e213586.
    PubMed     Abstract available


    April 2025
  156. ZELIKOVICH AS, Zamorska B, Michaelson NM
    Patient Perspectives: Patient as Teacher: The Impact of Listening to a Patient With Stiff-Person Syndrome on Her Disease Course.
    Neurology. 2025;104:e213433.
    PubMed     Abstract available


  157. NAKAJIMA A, Hokari M, Yanagimura F, Saji E, et al
    Long-Term Clinical Landscapes of Spinal Hypertrophic Pachymeningitis With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Neurology. 2025;104:e213420.
    PubMed     Abstract available


  158. AL-SALAHAT A, Abdul Jabbar AB, Sharma R, Chen YT, et al
    Demographic and Geographic Trends in Myasthenia Gravis-Related Mortality in the United States, 1999-2022.
    Neurology. 2025;104:e213505.
    PubMed     Abstract available


  159. ABBOUD H, Clardy SL, Dubey D, Wickel J, et al
    The Clinical Trial Landscape in Autoimmune Encephalitis: Challenges and Opportunities.
    Neurology. 2025;104:e213487.
    PubMed     Abstract available


  160. BROWNLEE WJ, Foster MA, Pontillo G, Davagnanam I, et al
    Investigating Whether Dissemination in Time Is Essential to Diagnose Relapsing Multiple Sclerosis.
    Neurology. 2025;104:e210274.
    PubMed     Abstract available


  161. GANESH A, Galetta SL
    Editors' Note: Domestic Violence and Abuse in People Living With Multiple Sclerosis.
    Neurology. 2025;104:e213407.
    PubMed    


  162. VIDAL-JORDANA A, Ontaneda D
    To Kill Time: A Bold Step Toward Simplifying Multiple Sclerosis Diagnosis.
    Neurology. 2025;104:e213416.
    PubMed    


  163. MAHAJAN KR, Herman D, Zheng Y, Androjna C, et al
    Neurodegeneration and Demyelination in the Multiple Sclerosis Spinal Cord: Clinical, Pathological, and 7T MRI Perspectives.
    Neurology. 2025;104:e210259.
    PubMed     Abstract available


  164. MAVRIDIS A, Viktorisson A, Eliasson B, von Euler M, et al
    Risk of Ischemic and Hemorrhagic Stroke in Individuals With Type 1 and Type 2 Diabetes: A Nationwide Cohort Study in Sweden.
    Neurology. 2025;104:e213480.
    PubMed     Abstract available


  165. MCAREE M, Frontera JA
    Clinical Reasoning: A 56-Year-Old Woman With New-Onset Hoarseness and Dysphagia.
    Neurology. 2025;104:e213363.
    PubMed     Abstract available


    March 2025
  166. GOH WGW, Ng IKS, Tan MKX, Fong CYK, et al
    Clinical Reasoning: A 26-Year-Old Woman With Headache and Eosinophilia.
    Neurology. 2025;104:e213434.
    PubMed     Abstract available


  167. MAILLART E, Dubessy AL, Shor N, Piljan M, et al
    Severe Relapse After Switching From Eculizumab to Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e213399.
    PubMed     Abstract available


  168. GOMEZ-FIGUEROA E, Moreno-Bernardino CJ, De Alba-Sanchez AM, Guerrero-Udave N, et al
    The Burden of Multiple Sclerosis in Mexico.
    Neurology. 2025;104:e213343.
    PubMed     Abstract available


    February 2025
  169. TRANFA M, Petracca M, Moccia M, Scaravilli A, et al
    Conventional MRI-Based Structural Disconnection and Morphometric Similarity Networks and Their Clinical Correlates in Multiple Sclerosis.
    Neurology. 2025;104:e213349.
    PubMed     Abstract available


  170. MARRIE RA, Bolton J, Ling YV, Bernstein C, et al
    Peripartum Mental Illness in Mothers With Multiple Sclerosis and Other Chronic Diseases in Ontario, Canada.
    Neurology. 2025;104:e210170.
    PubMed     Abstract available


  171. DERSCH RS, Fingerle V, Berns J, Rauer S, et al
    Pearls & Oy-sters: Recurrent Lyme Neuroborreliosis With Seroreversion in a Patient With Multiple Sclerosis on a B-Cell Depleting Therapy.
    Neurology. 2025;104:e213330.
    PubMed     Abstract available


  172. ROSS LA
    Peripartum Mental Illness in Mothers With Multiple Sclerosis Merits Neurologists' Attention.
    Neurology. 2025;104:e213366.
    PubMed    


  173. CERQUEIRA JJ, Berthele A, Cree BAC, Filippi M, et al
    Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label Extension.
    Neurology. 2025;104:e210142.
    PubMed     Abstract available


  174. COBO-CALVO A, Carbonell-Mirabent P, Tur C, Otero-Romero S, et al
    Age-Related Disability Outcomes After a First Demyelinating Event.
    Neurology. 2025;104:e210305.
    PubMed     Abstract available


  175. KRYSKO KM, Waltz M, Chitnis T, Weinstock-Guttman B, et al
    Study of the Association Between Menarche and Disease Course in Pediatric Multiple Sclerosis.
    Neurology. 2025;104:e210213.
    PubMed     Abstract available


  176. ROCCA MA, Preziosa P, Filippi M
    Age Matters in Multiple Sclerosis: Novel Insights Into Disease Progression From Clinical Onset.
    Neurology. 2025;104:e213396.
    PubMed    


  177. BRENTON JN
    Menarche and Relapses in Multiple Sclerosis: Associations Between a Physiologic Developmental Milestone and Disease Activity.
    Neurology. 2025;104:e213321.
    PubMed    


  178. BALCOM EF, Mccombe JA, Kate MP, Vu K, et al
    Inequities in the Use of Disease-Modifying Therapy Among Adults Living With Multiple Sclerosis in Urban and Rural Areas in Alberta, Canada.
    Neurology. 2025;104:e210251.
    PubMed     Abstract available


  179. CARVAJAL R, Guananga-Alvarez D, Tur C, Esperalba J, et al
    Effect of the Number of Vaccine Doses Before Starting Anti-CD20 Therapy on Seroprotection Rates Against Hepatitis B Virus in People With MS.
    Neurology. 2025;104:e210281.
    PubMed     Abstract available


  180. AMEZCUA L, Cardenas-Iniguez C, Orlando C, Martinez A, et al
    Person-Centered Social Determinants and Neighborhood-Level Deprivation Associated With Disability in Hispanic People With Multiple Sclerosis.
    Neurology. 2025;104:e213332.
    PubMed     Abstract available



  181. Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis.
    Neurology. 2025;104:e210299.
    PubMed    



  182. Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
    Neurology. 2025;104:e210298.
    PubMed    


    January 2025
  183. TSAI CC, Chen J, Pikula A, Johnson EL, et al
    Opinion & Special Articles: Beyond Pronouns-Educating Trainees on the Impact of Language on Gender Inclusivity in Neurologic Practice.
    Neurology. 2025;104:e210289.
    PubMed     Abstract available


  184. SILVERMAN HE, Bostrom A, Nylander AN, Akula A, et al
    Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis.
    Neurology. 2025;104:e210228.
    PubMed     Abstract available


  185. SALTER A, Lancia S, Cutter GR, Fox RJ, et al
    Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
    Neurology. 2025;104:e210149.
    PubMed     Abstract available


  186. CARVALHO IV, Gomes F, Almendra L, Geraldo A, et al
    Reversible Unilateral Tongue Border Atrophy Associated With Anti-Acetylcholine Receptor Antibody-Positive Myasthenia Gravis.
    Neurology. 2025;104:e210288.
    PubMed    


  187. CAGOL A, Montobbio N
    Reassuring Insights Into the Effect of COVID-19 on Symptoms and Disability in People With Multiple Sclerosis: Weathering the Storm.
    Neurology. 2025;104:e210272.
    PubMed    


  188. CRUCIANI A, Toosy AT
    Progression Independent of Relapse Activity in Multiple Sclerosis: More, or Less, Than Meets the Eye?
    Neurology. 2025;104:e210296.
    PubMed    


  189. STRIJBIS EMM, Mostert J, Comtois J, Salter A, et al
    Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis.
    Neurology. 2025;104:e210153.
    PubMed     Abstract available


  190. WONG SH, Abuzaitoun R, Cornblath WT, Eggenberger ER, et al
    Multicenter Validation of the Ocular Myasthenia Gravis Rating Scale Questionnaire.
    Neurology. 2025;104:e210150.
    PubMed     Abstract available


  191. MONGAY-OCHOA N, Pareto D, Alberich M, Carbonell-Mirabent P, et al
    Association of the Cervical Canal Area With Disability and Progression in People With Multiple Sclerosis.
    Neurology. 2025;104:e210136.
    PubMed     Abstract available


  192. CHEN B, Francis A, Cooper SA, Dobson R, et al
    Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2025;104:e210137.
    PubMed     Abstract available


  193. JUL JARBAEK NIELSEN J, Levison L, Andersen H
    Changes in Myasthenia Gravis Incidence in Denmark From 1985 to 2021: A Nationwide Population-Based Study.
    Neurology. 2025;104:e210139.
    PubMed     Abstract available


    December 2024
  194. RIMKUS CM, Nucci MP, Avolio IB, Apostolos-Pereira SL, et al
    Atrophy Patterns in Patients With Multiple Sclerosis With Cognitive Impairment, Fatigue, and Mood Disorders.
    Neurology. 2024;103:e210080.
    PubMed     Abstract available


  195. BRENNER J, Ruhe CJ, Kulderij I, Bastiaansen AEM, et al
    Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis.
    Neurology. 2024;103:e210109.
    PubMed     Abstract available


  196. SIRIRATNAM P, Huda S, Van Der Walt A, Sanfilippo PG, et al
    Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
    Neurology. 2024;103:e209940.
    PubMed     Abstract available


  197. ROSS R, O'Neill KA, Betensky RA, Billiet T, et al
    Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis.
    Neurology. 2024;103:e210140.
    PubMed     Abstract available


  198. HARTUNG HP, Benedict RHB, Berger T, Bermel RA, et al
    Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label Trial.
    Neurology. 2024;103:e210049.
    PubMed     Abstract available


  199. CRANE PD, Sillau S, Dreher R, Fix R, et al
    Population-Based Study of the Epidemiology of Stiff Person Syndrome in a Large Colorado-Based Health System.
    Neurology. 2024;103:e210078.
    PubMed     Abstract available


  200. KLEIN CJ, Triplett JD, Murray DL, Gorsh AP, et al
    Optimizing Anti-Myelin-Associated Glycoprotein and IgM-Gammopathy Testing for Neuropathy Treatment Evaluation.
    Neurology. 2024;103:e210000.
    PubMed     Abstract available


  201. QUINN CM, Rajarajan P, Gill AJ, Kopinsky H, et al
    Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
    Neurology. 2024;103:e210003.
    PubMed     Abstract available


  202. WILSON E, Meeks HD, Barney BJ, Waltz M, et al
    Epidemiology and Impact of Social Hardships in Children With Multiple Sclerosis in the United States.
    Neurology. 2024;103:e209991.
    PubMed     Abstract available


    November 2024
  203. REEVES JA, Bartnik A, Jakimovski D, Mohebbi M, et al
    Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis.
    Neurology. 2024;103:e210004.
    PubMed     Abstract available


  204. WATANABE M, Isobe N, Niino M, Nakashima I, et al
    Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey.
    Neurology. 2024;103:e209992.
    PubMed     Abstract available


  205. SANTILLI AR, Ni O, Milone M, Selcen D, et al
    Immune-Mediated Megaconial Myopathy: A Novel Subtype of Autoimmune Myopathy.
    Neurology. 2024;103:e210001.
    PubMed     Abstract available


  206. GUSOVSKY AV, Lin CC, Kerber K, Reynolds EL, et al
    Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications.
    Neurology. 2024;103:e210029.
    PubMed     Abstract available


  207. SHARMA R, Bellacicco NJ, Husar WG, Park JH, et al
    Pearls & Oy-sters: Breaking Bad CIDP: Recognition of Anti-NF155 Autoimmune Nodopathy in Refractory CIDP.
    Neurology. 2024;103:e209848.
    PubMed    


  208. MICHAELSON NM, Klawiter EC, Singhal T
    Journal Club: PET Imaging in Multiple Sclerosis and Its Prognostic Implications.
    Neurology. 2024;103:e210047.
    PubMed    


  209. PONTILLO G, Prados F, Colman J, Kanber B, et al
    Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap.
    Neurology. 2024;103:e209976.
    PubMed     Abstract available


  210. BRUCKMAN D, Lee I, Schold JD, Claytor BR, et al
    Epidemiologic Study of Myasthenia Gravis in the Elderly US Population: A Longitudinal Analysis of the Medicare Claims Database, 2006-2019.
    Neurology. 2024;103:e210005.
    PubMed     Abstract available



  211. Predicting Outcome in Guillain-Barre Syndrome: International Validation of the Modified Erasmus GBS Outcome Score.
    Neurology. 2024;103:e209968.
    PubMed    


  212. BROEDERS TAA, van Dam M, Pontillo G, Rauh V, et al
    Energy Associated With Dynamic Network Changes in Patients With Multiple Sclerosis and Cognitive Impairment.
    Neurology. 2024;103:e209952.
    PubMed     Abstract available


  213. PIERRET C, Mulliez A, Le Bihan-Benjamin C, Moisset X, et al
    Cancer Risk Among Patients With Multiple Sclerosis: A 10-Year Nationwide Retrospective Cohort Study.
    Neurology. 2024;103:e209885.
    PubMed     Abstract available


  214. GUPTA J, Choudhary R, Gupta A, Sharma P, et al
    Child Neurology: Acute Necrotizing Encephalopathy of Childhood Associated With Dengue: Good Neurologic Outcome Despite a Fulminant Presentation.
    Neurology. 2024;103:e209954.
    PubMed     Abstract available


  215. SIEGLER JE, Galetta SL
    Editors' Note: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209934.
    PubMed    


  216. MOEHLMAN M
    Author Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209565.
    PubMed    


  217. YANG Y, Li J, Tang Y
    Reader Response: Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;103:e209545.
    PubMed    


  218. MARIGNIER R, Kunchok A
    Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines.
    Neurology. 2024;103:e209970.
    PubMed    


  219. RINGELSTEIN M, Asseyer S, Lindenblatt G, Fischer K, et al
    Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
    Neurology. 2024;103:e209888.
    PubMed     Abstract available


    October 2024
  220. SILVERMAN A, Sasaki M, Espindola Lima JE, Cheronis C, et al
    Child Neurology: Remarkable Recovery From Severe Acute Necrotizing Encephalopathy.
    Neurology. 2024;103:e209877.
    PubMed     Abstract available


  221. XU TT, Kaplan TM, Chen JJ
    Teaching NeuroImages: Cilioretinal Artery Occlusion Secondary to Antiphospholipid Syndrome.
    Neurology. 2024;103:e209901.
    PubMed    


  222. SIEGLER JE 3RD, Galetta S
    Editors' Note: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209893.
    PubMed    


  223. GROBOIS L, You M, Etienne M
    Reader Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209508.
    PubMed    


  224. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Author Response: Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;103:e209515.
    PubMed    


  225. HAY M, Rollot F, Casey R, Kerbrat A, et al
    Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study.
    Neurology. 2024;103:e209886.
    PubMed     Abstract available


  226. YOKOTE H, Mori K, Nakamichi K, Matsuda T, et al
    Global Hyperperfusion in the Brain at Onset of the Immune Reconstitution Inflammatory Syndrome in a Patient With Natalizumab-Associated PML.
    Neurology. 2024;103:e209874.
    PubMed    


  227. ROBERTS JI, Ng D, Kapadia R
    Pearls & Oy-sters: Tumour-Like Mass Lesion Secondary to Primary CNS Vasculitis.
    Neurology. 2024;103:e209819.
    PubMed     Abstract available



  228. Patient and Physician Perspectives on the Wearing-Off Effect in Multiple Sclerosis: Results From Structured Interviews (P1-6.015).
    Neurology. 2024;103:e209905.
    PubMed    



  229. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;103:e209461.
    PubMed    


  230. LOONSTRA FC, Alvarez Sirvent D, Tesi N, Holstege H, et al
    Association of Polygenic Risk Score With Lifetime Risk of Developing Multiple Sclerosis in a Population-Based Birth-Year Cohort.
    Neurology. 2024;103:e209663.
    PubMed     Abstract available


  231. BLACKOWICZ M, James J, McNeil-Posey K, Schwartz T, et al
    Socioeconomic Factors Associated with >/=2-year Delayed Diagnosis of Neuromyelitis Optica Spectrum Disorder (NMOSD) in the United States.
    Neurology. 2024;103.
    PubMed     Abstract available


  232. MANGIORIS G, Orozco E, Dubey D, Flanagan E, et al
    Long-Term Outcomes in Antibody-Negative Autoimmune Encephalitis: A Retrospective Study.
    Neurology. 2024;103.
    PubMed     Abstract available


  233. VENKATARAMAN I, Ott A, Miske R, Scharf M, et al
    Performance Assessment of the New EUROLINE Neurologic Syndrome 15 Ag (IgG) for the Determination of Autoantibodies Associated with Neurological Disorders.
    Neurology. 2024;103.
    PubMed     Abstract available


    September 2024
  234. ROHM Z, Mobley B, Pawate S
    Teaching NeuroImage: Immunoglobulin G4-Related Hypophysitis.
    Neurology. 2024;103:e209809.
    PubMed    


  235. ROVIRA A, Pareto D
    chi-Separation as a Novel MRI Biomarker for Assessing Disease Progression in Multiple Sclerosis: Divide and Conquer.
    Neurology. 2024;103:e209735.
    PubMed    


  236. MULLER J, Lu PJ, Cagol A, Ruberte E, et al
    Quantifying Remyelination Using chi-Separation in White Matter and Cortical Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209604.
    PubMed     Abstract available


  237. BOURDETTE D
    Investigating When Patients With Multiple Sclerosis Should Switch From a Low- or Moderate-Efficacy Therapy to a High-Efficacy Treatment.
    Neurology. 2024;103:e209835.
    PubMed    


  238. BSTEH G, Aicher ML, Walde JF, Krajnc N, et al
    Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
    Neurology. 2024;103:e209752.
    PubMed     Abstract available


  239. BANKS SA, Brinjikji W, Giannini C, Syc-Mazurek SB, et al
    Intra-arterial Melphalan as Targeted Therapy for Tumefactive Multiple Sclerosis Lesions.
    Neurology. 2024;103:e209739.
    PubMed    


  240. ZARA P, Solla P, Damato V, Sechi E, et al
    Teaching Video NeuroImage: The "Chameleon Eyes Sign" in Myasthenia Gravis.
    Neurology. 2024;103:e209756.
    PubMed    


  241. SHIMIZU A, Noguchi-Shinohara M, Komatsu J, Ono K, et al
    Multifocal Intracranial Rosai-Dorfman Disease Mimicking Immunoglobulin G4-Related Pachymeningitis.
    Neurology. 2024;103:e209741.
    PubMed    


  242. ABBOUD H, Farez MF
    The Risk of Multiple Sclerosis Relapse After Vaccination: Can a Population-Based Study of Mass Vaccination End the Longstanding Debate?
    Neurology. 2024;103:e209761.
    PubMed    


  243. MOISSET X, Leray E, Chenaf C, Taithe F, et al
    Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.
    Neurology. 2024;103:e209662.
    PubMed     Abstract available


    August 2024
  244. KARALIUS M, Mohan S, Paredes D, Rasool N, et al
    Pearls & Oy-sters: Optic Neuritis as First Demyelinating Event During Pregnancy in 2 Young Hispanic Women: MS vs MOGAD.
    Neurology. 2024;103:e209706.
    PubMed     Abstract available


  245. PASCUAL-GONI E, Caballero-Avila M, Querol L
    Antibodies in Autoimmune Neuropathies: What to Test, How to Test, Why to Test.
    Neurology. 2024;103:e209725.
    PubMed     Abstract available


  246. MENON D, Alharbi M, Katzberg HD, Bril V, et al
    Effect of Immunosuppression in Risk of Developing Generalized Symptoms in Ocular Myasthenia Gravis: A Retrospective Cohort Study.
    Neurology. 2024;103:e209722.
    PubMed     Abstract available


  247. TAGA A, Wali A, Eberhart CG, Green KE, et al
    Teaching NeuroImage: Giant Cell Arteritis With Optic Perineuritis.
    Neurology. 2024;103:e209707.
    PubMed    


  248. WANG W
    Reader Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209441.
    PubMed    


  249. WU J, Guo K, Liu J
    Author Response: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209463.
    PubMed    


  250. LEWIS A, Galetta SL
    Editors' Note: Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;103:e209736.
    PubMed    



  251. Characterization Profiles of ANCA-associated Vasculitis With Neurological Manifestations (P7-14.007).
    Neurology. 2024;103:e209640.
    PubMed    



  252. Artificial Intelligence-Based Ocular Motor Biomarkers for Myasthenia Gravis Diagnosis (P10-11.016).
    Neurology. 2024;103:e209639.
    PubMed    


  253. MAYCOCK TJ, Rossor T, Vanegas M, Gringras P, et al
    Child Neurology: Common Occurrence of Narcolepsy Type 1 and Myasthenia Gravis.
    Neurology. 2024;103:e209598.
    PubMed     Abstract available


  254. SASTRE-GARRIGA J, Vidal-Jordana A, Toosy AT, Enzinger C, et al
    Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives.
    Neurology. 2024;103:e209677.
    PubMed     Abstract available


  255. WILLIAMS MJ, Amezcua L, Cohan SL, Cohen JA, et al
    Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses.
    Neurology. 2024;103:e209610.
    PubMed     Abstract available


    July 2024
  256. PFEUFFER S, Wolff S, Aslan D, Rolfes L, et al
    Association of Clinical Relapses With Disease Outcomes in Multiple Sclerosis Patients Older Than 50 Years.
    Neurology. 2024;103:e209574.
    PubMed     Abstract available


  257. GRANGEON L, Boulouis G, Capron J, Bala F, et al
    Cerebral Amyloid Angiopathy-Related Inflammation and Biopsy-Positive Primary Angiitis of the CNS: A Comparative Study.
    Neurology. 2024;103:e209548.
    PubMed     Abstract available


  258. GAVAZZI F, Vaia Y, Woidill S, Formanowski B, et al
    Nonverbal Cognitive Skills in Children With Aicardi Goutieres Syndrome.
    Neurology. 2024;103:e209541.
    PubMed     Abstract available


  259. CICCARELLI O, Barkhof F, Calabrese M, De Stefano N, et al
    Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis.
    Neurology. 2024;103:e209444.
    PubMed     Abstract available


  260. MADSEN MA, Povazan M, Wiggermann V, Lundell H, et al
    Association of Cortical Lesions With Regional Glutamate, GABA, N-Acetylaspartate, and Myoinositol Levels in Patients With Multiple Sclerosis.
    Neurology. 2024;103:e209543.
    PubMed     Abstract available


    June 2024
  261. KAMINSKI HJ, Kusner LL, Cutter GR, Le Panse R, et al
    Does Surgical Removal of the Thymus Have Deleterious Consequences?
    Neurology. 2024;102:e209482.
    PubMed     Abstract available


  262. PALLADINO R, Monasta L
    Estimating the Prevalence and Burden of Multiple Sclerosis in China Using the Global Burden of Disease Study: Challenges and Future Directions.
    Neurology. 2024;102:e209521.
    PubMed    


  263. ZHANG C, Liu W, Wang L, Wang F, et al
    Prevalence and Burden of Multiple Sclerosis in China, 1990-2019: Findings From the Global Burden of Disease Study 2019.
    Neurology. 2024;102:e209351.
    PubMed     Abstract available


    May 2024
  264. CACCIAGUERRA L, Abdel-Mannan O, Champsas D, Mankad K, et al
    Radiologic Lag and Brain MRI Lesion Dynamics During Attacks in MOG Antibody-Associated Disease.
    Neurology. 2024;102:e209303.
    PubMed     Abstract available


  265. SILBERMANN E, Spain RI
    Serum Neurofilament Light Chain for Multiple Sclerosis Relapses: Too Little Too Late?
    Neurology. 2024;102:e209456.
    PubMed    


  266. FOX RJ, Cree BAC, de Seze J, Gold R, et al
    Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209357.
    PubMed     Abstract available


  267. VALKO Y, Wirth MA, Fierz FC, Schesny MK, et al
    Accuracy of Repetitive Ocular Vestibular-Evoked Myogenic Potentials to Diagnose Myasthenia Gravis in Patients With Ptosis or Diplopia.
    Neurology. 2024;102:e209395.
    PubMed     Abstract available


  268. LIAO J, Lu Y, Lu Y, Huang Y, et al
    Cardiopulmonary Coupling Spectrogram as an Ambulatory Method for Assessing Sleep Disorders in Patients With Autoimmune Encephalitis.
    Neurology. 2024;102:e209302.
    PubMed     Abstract available


  269. MICHAELSON NM
    Right Brain: The Unraveling.
    Neurology. 2024;102:e209492.
    PubMed     Abstract available


  270. VYAS MV, Kapral MK, Alonzo R, Fang J, et al
    Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants.
    Neurology. 2024;102:e209350.
    PubMed     Abstract available


  271. TANG A, Yoshida K, Lahey H, Wilcox DR, et al
    Herpes Simplex Virus Encephalitis in Patients With Autoimmune Conditions or Exposure to Immunomodulatory Medications.
    Neurology. 2024;102:e209297.
    PubMed     Abstract available


    April 2024
  272. ZOUVELOU V, Petrou EM, Strataki E, Vasileiou V, et al
    Pearls & Oy-sters: Thyroid-Associated Ophthalmopathy and Transient Neuromuscular Junction Disorder Due to Graves Disease.
    Neurology. 2024;102:e209282.
    PubMed     Abstract available


  273. DEMORTIERE S, Joubert B, Benaiteau M, Hilezian F, et al
    Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis.
    Neurology. 2024;102:e209284.
    PubMed    


  274. MOEHLMAN M, Kornbluh AB
    Teaching NeuroImage: Anti-NMDA Receptor Encephalitis Presenting With Cerebellitis in a Pediatric Patient.
    Neurology. 2024;102:e209259.
    PubMed    



  275. Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria: A Longitudinal, Prospective, Multicenter Study.
    Neurology. 2024;102:e209214.
    PubMed    


  276. OYAMA M, Holzer MT, Ohnuki Y, Saito Y, et al
    Pathologic Features of Anti-Ku Myositis.
    Neurology. 2024;102:e209268.
    PubMed     Abstract available


  277. OLIVE-CIRERA G, Bruijstens AL, Fonseca EG, Chen LW, et al
    MOG Antibodies Restricted to CSF in Children With Inflammatory CNS Disorders.
    Neurology. 2024;102:e209199.
    PubMed     Abstract available


  278. SPELMAN T, Simoneau G, Hyde R, Kuhelj R, et al
    Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
    Neurology. 2024;102:e208114.
    PubMed     Abstract available


  279. TOGNI CL, Frontzek K, Schubring-Giese M, Imbach LL, et al
    Posttransplant Anti-GABA(A) Receptor Antibody-Associated Autoimmune Encephalitis.
    Neurology. 2024;102:e209245.
    PubMed    


  280. THAKOLWIBOON S, Dubey D
    Redefining Patient Evaluation in Anti-IgLON5 Disease: Anti-IgLON5 Disease Composite Score.
    Neurology. 2024;102:e209213.
    PubMed    


  281. GAIG C, Gruter T, Heidbreder A, Sabater L, et al
    Development of a Composite Score for the Clinical Assessment of Anti-IgLON5 Disease.
    Neurology. 2024;102:e208101.
    PubMed     Abstract available


  282. KOTHAPALLI NP, Chompoopong P, McKeon A, Dubey D, et al
    Teaching Video NeuroImage: Adaptor-Related Protein-Complex-3 Subunit beta-2 Immunoglobulin-G-Associated Autoimmune Ataxia.
    Neurology. 2024;102:e209257.
    PubMed    


  283. AGYEI P, Chen M, Guo Y, Perez CA, et al
    Pearls & Oy-sters: KLHL11 IgG Paraneoplastic-Associated Hearing Loss and Rhombencephalitis in a Woman With Metastatic Mullerian Tumor.
    Neurology. 2024;102:e209187.
    PubMed     Abstract available


  284. KUHLMANN G, Cloud B
    Characterization of the Earliest Adopters of Subcutaneous FcRn Blockers for gMG (P4-14.013).
    Neurology. 2024;102.
    PubMed     Abstract available


  285. YU Y, Kushlaf H
    Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
    Neurology. 2024;102.
    PubMed     Abstract available


  286. MASCANFRONI I, Manasson J, Pellerin A, Sanmarco L, et al
    Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases (P4-14.018).
    Neurology. 2024;102.
    PubMed     Abstract available


  287. WATANABE F, Fedorko J, Imitola J
    Dimethyl Fumarate Enhances Neural Stem Cell (NSC) Self-renewal and Neuroprotection in a Human Cellular Model of Multiple Sclerosis Inflammation-induced Neurodegeneration (P8-6.014).
    Neurology. 2024;102.
    PubMed     Abstract available


  288. OHRN S, Patel R, Ali A, Bauerschmidt A, et al
    Autonomic Dysfunction in Autoimmune Encephalitis: A Review of the Literature (P6-14.004).
    Neurology. 2024;102.
    PubMed     Abstract available


  289. ZAJNER C, Patil N, McInnis R, Van Uum S, et al
    Patterns of Extraocular Muscle Enlargement in Graves' Disease and Acromegaly (P7-10.005).
    Neurology. 2024;102.
    PubMed     Abstract available


  290. ROBERTS K, Cohn B, Sista SR
    Acetylcholine Binding Receptor Positivity from Passive Antibody Transfer in a Case of Progressive Muscular Atrophy (P11-11.009).
    Neurology. 2024;102.
    PubMed     Abstract available


  291. WEBER A, Rose J, DeWitt L
    NMOSD: Previously Seropositive Patient Presents with Seronegative Brainstem Attack (P11-14.017).
    Neurology. 2024;102.
    PubMed     Abstract available


  292. LOBAINA M, Valaparla VL, Shanina E
    Vogt-Koyanagi-Harada Disease an Autoimmune Comorbidity of Multiple Sclerosis, Not Just a Mimicker (P3-14.014).
    Neurology. 2024;102.
    PubMed     Abstract available


  293. HABIB AA, Kaminski HJ, Grosskreutz J, Mantegazza R, et al
    Clinically Meaningful Improvement in Physical Fatigue and Muscle Weakness Fatigability with Rozanolixizumab: Post-hoc Analysis of MG Symptoms PRO Responder Rate in the MycarinG study (P4-11.001).
    Neurology. 2024;102.
    PubMed     Abstract available


  294. KARAYI G, Quinones-Herrero N, Martin J, Chaudhry S, et al
    A Retrospective Analysis of Disease Modifying Drug Discontinuation in Patients with Multiple Sclerosis (S31.010).
    Neurology. 2024;102.
    PubMed     Abstract available


  295. ROSE M, Hsu S, Balan A, Anderson A, et al
    Risk Factors for Peripartum Mood Disorders in Women with MS: A Prospective Study (P4-6.014).
    Neurology. 2024;102.
    PubMed     Abstract available


  296. JAFFRY K, Karpenos S, Lin J, Matos J, et al
    Climate Change Associated with Declining Clinical Outcomes in Myasthenia Gravis for US States with the Greatest Temperature Increase (P4-14.004).
    Neurology. 2024;102.
    PubMed     Abstract available


  297. MAKAROVA A, Raju S, Ciotti J
    Parainfectious Hemorrhagic Longitudinally-extensive Transverse Myelitis Secondary to COVID-19 (P1-13.010).
    Neurology. 2024;102.
    PubMed     Abstract available


  298. WOODSON S, Gettings E, Guo CY, Klineova S, et al
    Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).
    Neurology. 2024;102.
    PubMed     Abstract available


  299. VARNET M, Kayani S, Wang C
    Diagnostic Journey and Therapeutic Intervention of a Type-1 Interferonopathy in a Newborn (P6-8.002).
    Neurology. 2024;102.
    PubMed     Abstract available


  300. MIKAMI T, Levy M
    Association of HLA-DRB1*15:01 Status with Transcriptomic Pattern of B cells in CSF in Multiple Sclerosis (P7-6.011).
    Neurology. 2024;102.
    PubMed     Abstract available


    March 2024
  301. YOUNG A, Johnston JL
    Pearls & Oy-sters: Ocular Myasthenia Gravis: Central Ocular Motor Signs and Unilateral Visual Loss Caused by the Great Neuro-Ophthalmologic Impersonator.
    Neurology. 2024;102:e209260.
    PubMed     Abstract available


  302. AOTSUKA Y, Misawa S, Suichi T, Shibuya K, et al
    Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
    Neurology. 2024;102:e209130.
    PubMed     Abstract available


  303. MARRIE RA, Salter A
    Off-Road Testing: Outcome Reporting Bias in Multiple Sclerosis Trials.
    Neurology. 2024;102:e208099.
    PubMed    


  304. LEMMENS CMC, van Amerongen S, Strijbis EM, Killestein J, et al
    Outcome Reporting Bias in Clinical Trials Researching Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e208032.
    PubMed     Abstract available


  305. BOURDETTE D, Wooliscroft L
    The Challenges of Treating Late-Onset Multiple Sclerosis.
    Neurology. 2024;102:e209146.
    PubMed    


  306. MOURESAN EF, Mentesidou E, Berglund A, Mckay KA, et al
    Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Neurology. 2024;102:e208051.
    PubMed     Abstract available



  307. Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e209252.
    PubMed    


  308. SALTER A, Lancia S, Kowalec K, Fitzgerald KC, et al
    Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations.
    Neurology. 2024;102:e209135.
    PubMed     Abstract available


  309. CHARD DT
    Chronically Active Lesions as a Trial Outcome in Multiple Sclerosis: A New Perspective on an Old Foe.
    Neurology. 2024;102:e209246.
    PubMed    


  310. ARNOLD DL, Elliott C, Martin EC, Hyvert Y, et al
    Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
    Neurology. 2024;102:e208058.
    PubMed     Abstract available


  311. PAPP V, Magyari M, Moller S, Sellebjerg F, et al
    Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
    Neurology. 2024;102:e209147.
    PubMed     Abstract available


    February 2024
  312. MORGAN A, Li Y, Thompson NR, Milinovich A, et al
    Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis.
    Neurology. 2024;102:e208019.
    PubMed     Abstract available


  313. RADZIK AM, Amezcua L, Anderson A, Gilmore S, et al
    Disparities by Race in Pregnancy Care and Clinical Outcomes in Women With Multiple Sclerosis: A Diverse Multicenter Cohort.
    Neurology. 2024;102:e208100.
    PubMed     Abstract available


  314. BRANCH A, Nuaaman MM, Appleton CT, Connaughton DM, et al
    Teaching NeuroImage: Extensive Brainstem and Striatal Involvement in Neuropsychiatric Systemic Lupus Erythematosus.
    Neurology. 2024;102:e209153.
    PubMed    


  315. GALBUSERA R, Bahn E, Weigel M, Cagol A, et al
    Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
    Neurology. 2024;102:e207966.
    PubMed     Abstract available


  316. WU J, Guo K, Liu J
    Partially Reversible FLAIR Hyperintensity Along the Brainstem Surface in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy.
    Neurology. 2024;102:e208064.
    PubMed     Abstract available


  317. NG HS, Zhu F, Zhao Y, Yao S, et al
    Adverse Events Associated With Disease-Modifying Drugs for Multiple Sclerosis.
    Neurology. 2024;102:e208006.
    PubMed     Abstract available


  318. BELLUCCI M, Castellano C, Marinelli L, Garbarino L, et al
    Patient With Rigidity and Fasciculations.
    Neurology. 2024;102:e208110.
    PubMed     Abstract available


  319. BRIDGE F, Brotherton J, Stankovich J, Sanfilippo PG, et al
    Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies.
    Neurology. 2024;102:e208059.
    PubMed     Abstract available


    January 2024
  320. GIBSON S, Mcgraw C
    Teaching NeuroImage: Cryptococcus in a Woman With Multiple Sclerosis on Fingolimod.
    Neurology. 2024;102:e208027.
    PubMed     Abstract available


  321. ANTOZZI C, Guptill J, Bril V, Gamez J, et al
    Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis.
    Neurology. 2024;102:e207937.
    PubMed     Abstract available


  322. MCGINLEY MP, Harvey T, Lopez R, Ontaneda D, et al
    Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care in the United States.
    Neurology. 2024;102:e207916.
    PubMed     Abstract available


  323. HABIB AA, Sacks N, Cool C, Durgapal S, et al
    Hospitalizations and Mortality From Myasthenia Gravis.
    Neurology. 2024;102:e207863.
    PubMed     Abstract available


  324. LANGER-GOULD A, Sotirchos ES, Bourdette D
    Rituximab for Multiple Sclerosis.
    Neurology. 2024;102:e208063.
    PubMed     Abstract available


  325. GALETTA S, Brownlee W
    Assignment Completed.
    Neurology. 2024;102:e207913.
    PubMed     Abstract available


  326. TUR C, Rocca MA
    Progression Independent of Relapse Activity in Multiple Sclerosis.
    Neurology. 2024;102:e207936.
    PubMed     Abstract available


  327. VIDAL-JORDANA A, Rovira A, Calderon W, Arrambide G, et al
    Adding the Optic Nerve in Multiple Sclerosis Diagnostic Criteria.
    Neurology. 2024;102:e200805.
    PubMed     Abstract available


  328. CAGOL A, Benkert P, Melie-Garcia L, Schaedelin SA, et al
    Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS.
    Neurology. 2024;102:e207768.
    PubMed     Abstract available


  329. VLAHOVIC L, McDonald J, Hinman J, Tomczak A, et al
    Prevalence, Demographic, and Clinical Factors Associated With Cognitive Dysfunction in Patients With Neuromyelitis Optica Spectrum Disorder.
    Neurology. 2024;102:e207965.
    PubMed     Abstract available


  330. ALKABIE S, Gray MT, Lau JC, Barra L, et al
    Teaching NeuroImage: Unilateral Primary Angiitis of the CNS.
    Neurology. 2024;102:e208018.
    PubMed     Abstract available


    December 2023
  331. ROLLOT F, Uhry Z, Dantony E, Vukusic S, et al
    Comparison of 2 Methods for Estimating Multiple Sclerosis-Related Mortality.
    Neurology. 2023;101:e2483-e2496.
    PubMed     Abstract available


  332. SUNSHINE A, Mandle QJ, Cabal Herrera AM, Zapanta B, et al
    Pearls & Oy-sters: Leber Hereditary Optic Neuropathy-Plus Masquerading as Neuromyelitis Optica Spectrum Disorder in a 2-Year-Old Child.
    Neurology. 2023;101:e2585-e2588.
    PubMed     Abstract available


  333. GUINEBRETIERE O, Nedelec T, Gantzer L, Lekens BB, et al
    Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
    Neurology. 2023 Dec 5:10.1212/WNL.0000000000207981.
    PubMed     Abstract available


    November 2023
  334. LI X, Stitt D, Lanzino G, Giannini C, et al
    Teaching NeuroImage: Pachymeningitis and Aortitis as the Initial Presentation of Granulomatosis With Polyangiitis.
    Neurology. 2023;101:979-980.
    PubMed    


    October 2023
  335. SRIVASTAVA I, Van Haren K
    Immunotherapy in Autoimmune Encephalitis: So Many Options, So Few Guidelines.
    Neurology. 2023 Oct 25:10.1212/WNL.0000000000208026.
    PubMed    


  336. BOURDETTE D, Silbermann E
    What Are the Risks of Guillain-Barre Syndrome Following SARS-CoV-2 Infection and COVID-19 Vaccination?
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207998.
    PubMed    


  337. BISHARA H, Arbel A, Barnett-Griness O, Bloch S, et al
    Association Between Guillain-Barre Syndrome and COVID-19 Infection and Vaccination: A Population-Based Nested Case-Control Study.
    Neurology. 2023 Oct 18:10.1212/WNL.0000000000207900.
    PubMed     Abstract available


  338. YANG JH, Liu EN, Nguyen L, Dunn-Pirio A, et al
    Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
    Neurology. 2023 Oct 12:10.1212/WNL.0000000000207746.
    PubMed     Abstract available


  339. GUASP M, Dalmau J
    Searching for Neuronal Antibodies in Psychiatric Diseases: Uncertain Findings and Implications.
    Neurology. 2023;101:656-660.
    PubMed     Abstract available


  340. SOTIRCHOS ES, Hu C, Smith MD, Lord HN, et al
    Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis.
    Neurology. 2023 Oct 10:10.1212/WNL.0000000000207957.
    PubMed     Abstract available


  341. LE VU S, Bertrand M, Botton J, Jabagi MJ, et al
    Risk of Guillain-Barre Syndrome Following COVID-19 Vaccines: A Nationwide Self-controlled Case Series Study.
    Neurology. 2023 Oct 3:10.1212/WNL.0000000000207847.
    PubMed     Abstract available


    September 2023
  342. COBO-CALVO A, Tur C, Otero-Romero S, Carbonell-Mirabent P, et al
    Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
    Neurology. 2023;101:e1280-e1292.
    PubMed     Abstract available


  343. PALLADINO R, Strijbis EM
    How Far Are We in Translating the Multiple Sclerosis Prodromes in Clinical Practice?
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207989.
    PubMed    


  344. CHERTCOFF AS, Yusuf F, Zhu F, Evans C, et al
    Psychiatric Comorbidity During the Prodromal Period in Patients With Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207843.
    PubMed     Abstract available


  345. HUPPKE BM, Reinert M, Hummel-Abmeier H, Stark W, et al
    Pretreatment Neurofilament Light Chain Serum Levels, Early Disease Severity, and Treatment Response in Pediatric Multiple Sclerosis.
    Neurology. 2023 Sep 25:10.1212/WNL.0000000000207791.
    PubMed     Abstract available


  346. ALMRAMHI MM, Finan C, Storm CS, Schmidt AF, et al
    Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207777.
    PubMed     Abstract available


  347. BUYUKKURT A, Harroud A
    The Potential to Inform Statin Use in Multiple Sclerosis Through Human Genetics [re: WNL-2023-000524].
    Neurology. 2023 Sep 1:10.1212/WNL.0000000000207773.
    PubMed    


    July 2023
  348. QUINN C, Moulton K, Farwell M, Le W, et al
    Imaging With PET/CT of Diffuse CD8 T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207596.
    PubMed     Abstract available


  349. COUSTAL C, Goulabchand R, Labauge P, Guilpain P, et al
    Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207609.
    PubMed     Abstract available


  350. SCHWEITZER F, Laurent S, Cortese I, Fink GR, et al
    Progressive Multifocal Leukoencephalopathy: Pathogenesis, Diagnostic Tools, and Potential Biomarkers of Response to Therapy.
    Neurology. 2023 Jul 24:10.1212/WNL.0000000000207622.
    PubMed     Abstract available


    September 2022
  351. B SYC-MAZUREK S, Chen JJ, Morris P, Sechi E, et al
    Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease.
    Neurology. 2022 Sep 29. pii: WNL.0000000000201263.
    PubMed     Abstract available


    August 2022
  352. BASTERRA PP, Nombela F, Iriarte P, Del Rincon CR, et al
    Proprioceptive Stimuli as a New Type of Trigger for Epilepsy in Stiff Person Syndrome.
    Neurology. 2022 Aug 31. pii: WNL.0000000000201196.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum